Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cell Source, Inc.

Get SEC filing alerts via email and in your feed for Cell Source, Inc.

CLCS

Cell Source, Inc.

About Cell Source, Inc.

Cell Source, Inc. is a biotech company specializing in immunotherapy and cell therapy technologies. It develops proprietary immune management platforms, including Veto Cell and Veto CAR-T, to improve transplantation safety, reduce rejection, GvHD, and infections. Focused on blood cancers, organ failure, and autoimmune diseases, it licenses patents from Yeda Research and collaborates with MD Anderson to advance off-the-shelf, allogeneic treatments for broader patient access and improved outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cell Source, Inc.

1
1
Cell Source, Inc. Cell Source Reports $1.48 Million Net Loss and Increased Working Capital Deficiency in Q1 2025

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Cell Source, Inc. Cell Source Reports $4.5 Million Net Loss for Fiscal Year 2024, Focuses on Veto Cell Technology

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Cell Source, Inc. Cell Source, Inc. Reports Net Loss, Decreased Operating Expenses, and Advances Veto Cell Technology

Via official filing (AI summary) | over 1 year ago | 0 comments